Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ManCoProc

Financiado

Cerrado

Advanced manufacturing of drug substances by co-processing with excipients throu...

Advanced manufacturing of drug substances by co-processing with excipients through heteronucleation in a milifluidic device Pharmaceutical industry is starting to adopt the approach of continuous manufacturing, with as few unit operations as possible, to deliver drug products in a faster, robust, cheaper and sustainable way. Poor mechanical properties... ver más

31/03/2026

VSCHT

Presupuesto desconocido

Líder del proyecto

VYSOKA SKOLA CHEMICKOTECHNOLOGICKA V PRAZE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-01

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

VSCHT

Lider

Proyectos interesantes

INVESTIGACION Y DESARROLLO DE NUEVOS METODOS...

Chemical Engine...

Medical Technol...

2M€ Cerrado

DESARROLLO DE PROCESOS PARA LA FABRICACIÓN DE...

Chemical Engine...

Medical Technol...

4M€ Cerrado

SINTESIS QUIMICA DE PRINCIPIOS ACTIVOSFARMACE...

Chemical Engine...

Medical Technol...

955K€ Cerrado

DISEÑO DE NUEVAS SÍNTESIS QUÍMICAS PARA LA OB...

Chemical Engine...

Medical Technol...

767K€ Cerrado

METODOS DE SINTESIS QUIMICA DE PRINCIPIOS ACT...

Chemical Engine...

Medical Technol...

2M€ Cerrado

DESARROLLO DE NUEVOS METODOS DE SINTESIS QUIM...

Chemical Engine...

Medical Technol...

3M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 18 meses Fecha Inicio: 2024-09-01
Fecha Fin: 2026-03-31

Líder del proyecto

VYSOKA SKOLA CHEMICKOTECHNOLOGICKA V PRAZE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Pharmaceutical industry is starting to adopt the approach of continuous manufacturing, with as few unit operations as possible, to deliver drug products in a faster, robust, cheaper and sustainable way. Poor mechanical properties of many drug substances are a hindrance to this, making them unsuitable for direct compression into tablets without additional operations. This challenge can be solved by co-processing: joining the particles of such drugs to the particles of inactive substances known as excipients (e.g. lactose), normally used for tablets production. The aim of this project is to develop a universal drug-excipient co-processing (CP) platform based on surface crystallization or co-precipitation. A CP method in a milifluidic device will be optimised with a range of drugs with differing physicochemical properties. The relationships between them, as well as excipient properties, parameters of the method and structural and functional characteristics of the obtained composites will be thoroughly investigated. To this end, cutting edge techniques will be employed to analyse particle size, morphology, dissolution and mechanical behaviour. To demonstrate improved manufacturability, the prototype CP material will be used for direct compression, and the tablets quality will be evaluated according to European Pharmacopeia requirements. The project will enable the researcher to achieve professional maturity in the field of particle engineering, allowing to employ her skills both in academia and in pharmaceutical industry. The results of the research will have commercialisation value, being of interest to companies as a potential new platform in (pre)formulation portfolio. The project will contribute to the body of evidence informing the decisions of regulators on pharmaceutical co-processing. In the long term, such impact should advance the transformation towards continuous manufacturing of affordable, available and sustainable drug products.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores